Obagi products showed excellent results in a new clinical study published in the July edition of Aesthetic Surgery Journal.
The study measured results of patients who combined their BOTOX treatment with Obagi, versus a control group who used Botox and a placebo. A recent press release specifically reports that Obagi’s Condition and Enhance line “provides greater improvement in overall facial appearance, as well as increased patient satisfaction vs. Botox treatments with a placebo.” The Condition and Enhance line of Obagi products, also marketed as Obagi Nu-Derm, uses a combination of 4 percent hydroquinone and tretinoin.
About the Study
The 120 day study was a multi-center, randomized, investigator-masked, parallel-group study with 61 Botox patients. Patients were randomly prescribed either a hydroquinone system (cleanser, toner, 4% hydroquinone, exfoliant, and sunscreen) combined with 0.05% tretinoin cream, or a “standard skin care regimen” with cleanser, moisturizer, and sunscreen.
Results Found With Obagi
Patients in the Obagi group reported a significant improvement in fine lines, wrinkles and hyperpigmentation. Lead investigator Joel Schlessinger MD said: “This data clearly highlights the fact that by adding Condition & Enhance to injectable patients’ treatment regimen, patients are addressing multiple aspects of aging skin for optimal results.”
Investigators and patients alike were asked to evaluate the results. They found “significantly milder fine lines/wrinkles and hyperpigmentation at days 30, 90, and 120” in the combination group and patient surveys showed “superior overall ratings.”
Here’s a breakdown of the Obagi results and standard group’s results:
- 89 percent of the combined group was satisfied or extremely satisfied with their results.
- 93 percent of the Obagi group was satisfied or extremely satisfied with the treatment regimen.
- 100 percent of the Obagi Condition and Enhance group wished to continue treatment after the study.
- 12 percent of the “standard skincare group” was satisfied or extremely satisfied with their results and their treatment regimen.
According to ASAPS, “Patients using the hydroquinone system plus tretinoin believed that their study treatment had further enhanced the improvements attained with botulinum toxin type A compared to those using the standard skin care regimen (86% vs. 8%).”
Read more from the following sources:
- Obagi Corporate Press Release
- ASAPS: Winning Combination for Botox Patients
- Watch Videos of Obagi Results